Allphase Pharma Consulting, LLC
A Professional Service Provider for the Pharma Industry
When Roche inlicensed Polyphor’s anti-pseudomonas drug POL7080 in November 2013, it marked a turning point. It seemed that Big Pharma that had all but abandoned the field in the last decade and was getting engaged in anti-infectives again. When a Continue reading Polyphor POL7080 And The Journey to The Land of Pyocyanea (Part 1)
When a well-designed pivotal Phase 3 trial fails to show NI, it demands an explanation. While awaiting the company’s analysis of the data, many possible explanations are bandied about. So it was not surprising that the eravacycline cUTI study (IGNITE-2) Continue reading After ICAAC: Some More Thoughts on Eravacycline in cUTI and IGNITE-2
SH: My dear Watson, did you read the news of the astonishing debacle that befell Mme Erava and made the headlines, creating anxiety of hitherto unknown proportions in Tetraland? Dr.W.: A disaster of epic proportions, for sure, and a mystery, an Continue reading Mme Erava and The Mysterious Case of Auto-Combustion